mProX™ Human ETV6 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human ETV6 Stable Cell Line (S01YF-1023-PY141). Click the button above to contact us or submit your feedback about this product.
Morgan Jones (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Alex Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Suppression of ETV6 effectively led to a substantial elevation in the protein expression of TWIST1.
Two cell lines expressing the androgen receptor (AR) were subjected to transient transfection with ETV6-targeting siRNA (scr. vs. siETV6), followed by subsequent examination using a Western blot assay.
Ref: Tsai, Yuan-Chin, et al. "Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer." Molecular Cancer 17.1 (2018): 1-12.
Pubmed: 29455655
DOI: 10.1186/s12943-018-0785-1
Research Highlights
Eckardt, Jan-Niklas. et al. "Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia." Leukemia, 2023.
In a study conducted on 1606 newly diagnosed and intensively treated adult acute myeloid leukemia (AML) patients across multiple centers, genetic lesions of IKZF1 were found to be prevalent and associated with a specific mutation hotspot at N159S. While the role of IKZF1 mutations in acute lymphoblastic leukemia has been well-established, their function in AML and impact on patient outcomes remain unclear. AML patients with mutated IKZF1 showed alterations in several other genes, and were found to have a higher likelihood of anemia and thrombocytopenia. In both univariable and multivariable analyses, IKZF1 mutations were found to be independent markers of adverse risk, affecting complete remission rates, event-free, relapse-free, and overall survival. This risk persisted even in patients who underwent allogeneic hematopoietic stem cell transplantation. These negative outcomes were not solely attributed to the N159S mutation, indicating a broader role for IKZF1 mutations in AML risk assessment.
Eckardt, Jan-Niklas. et al. "Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia." Leukemia, 2023.
Pubmed:
37833543
DOI:
10.1038/s41375-023-02061-1
Gopal Gupta, Dikshat. et al. "A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia." Cancer, 2023.
Ph-like B-acute lymphoblastic leukemia (B-ALL) is a high-risk subtype of B-ALL that has clinical significance. Limited information is available on the frequency, characteristics, and treatment outcomes of Ph-like ALL cases in low- and middle-income countries. Therefore, it is imperative to develop an efficient and affordable method for detecting Ph-like ALL cases.
Gopal Gupta, Dikshat. et al. "A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia." Cancer, 2023.
Pubmed:
37819686
DOI:
10.1002/cncr.35051
